Kaitlyn Jeffcott
Neurology · Frisco, TXNPI 1235616558
Payments from drug & device makers
Across 780 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Livanova USA, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Biogen$920
- UCB, Inc.$840
- EMD Serono, Inc.$771
- plus $9K from 54 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$2001%
- Travel & lodging$9675%
- Food & beverage$16,58291%
- Education$2872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,152
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$715
- NURTEC ODT$483
- EMGALITY$247
- UBRELVY$247
- Mavenclad$220
- LEMTRADA$200
- TYSABRI$150
- Austedo XR$133
- AUSTEDO$128
- QULIPTA$125
- REYVOW$125
- Zilbrysq$125
- XCOPRI$124
- UPLIZNA$122
- BRILINTA$116
- GOCOVRI$114
- Leqembi$113
- KISUNLA$110
How this compares
$18,186 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $37,866 |
| QuliptaAtogepant | 25 | $32,651 |
| Nurtec OdtRimegepant Sulfate | 11 | $21,055 |
| RexultiBrexpiprazole | 11 | $18,842 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $9,723 |
| Lacosamide | 35 | $3,384 |
| Memantine Hcl | 78 | $2,063 |
| Levetiracetam | 18 | $1,609 |
| Primidone | 57 | $1,285 |
| Gabapentin | 49 | $1,225 |
| Amitriptyline Hcl | 31 | $782 |
| Pregabalin | 49 | $767 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 40 | $598 |
| Donepezil Hcl | 68 | $548 |
| Clonazepam | 21 | $535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $215 | $37,86623 claims |
| AbbVieQulipta | $3,315 | $32,65125 claims |
| PfizerNurtec Odt | $658 | $21,05511 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $196 | $18,84211 claims |
| Upsher-smith Laboratories LLCTopiramate | $162 | $16029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.
Other neurology in Frisco
- Ramin AnsariFrisco$838K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.